Gedatolisib Approved for PIK3CA-Wild-Type Breast Cancer

The indication covers adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed on or after endocrine therapy. It is expressly limited to tumors without a PIK3CA mutation. An untested tumor should therefore not be assumed to be wild type.

Gedatolisib (Revtorpyk) inhibits class I phosphatidylinositol 3-kinase and mammalian target of rapamycin signaling. The FDA authorized two regimens: gedatolisib plus fulvestrant and the same combination with the CDK4/6 inhibitor palbociclib. The approval creates distinct options rather than establishing that every eligible patient should receive the three-drug regimen.

Progression-free survival improved in VIKTORIA-1

The regulatory decision was supported by the phase 3 VIKTORIA-1 trial, which enrolled a PIK3CA-wild-type cohort of 351 patients. Participants had HR-positive, HER2-negative advanced breast cancer that had progressed after previous endocrine-based treatment that included a CDK4/6 inhibitor.

Patients were randomly assigned to gedatolisib plus fulvestrant and palbociclib, gedatolisib plus fulvestrant, or fulvestrant alone. Both gedatolisib-containing groups produced a statistically significant progression-free survival benefit over the fulvestrant control.

The hazard ratios correspond to estimated reductions of 76% and 67% in the instantaneous risk of progression or death, respectively, relative to fulvestrant alone. They should not be interpreted as the percentage of patients cured, the proportion who avoided progression altogether, or proof that one gedatolisib regimen is superior to the other.

Overall survival was not the basis for the reported benefit, and the FDA’s public approval summary did not provide a median follow-up duration for interpreting longer-term outcomes. Progression-free survival can support regulatory approval in advanced breast cancer, but it does not by itself establish longer survival or better quality of life.

Who falls within the new indication

Three clinical and molecular features define the approved population. The cancer must be HR-positive and HER2-negative; it must be unresectable locally advanced or metastatic; and disease must have progressed on or after endocrine therapy. Testing must also show no PIK3CA mutation.

That last requirement is central. PIK3CA-wild-type status is not interchangeable with unknown status, and the approval should not be generalized to patients with a detected PIK3CA mutation. Clinicians will need to establish whether an available tissue or blood result adequately characterizes the current advanced cancer, considering specimen quality, timing and the testing approach specified by the FDA-approved labeling.

The evidence is especially applicable to patients whose disease progressed after combined endocrine and CDK4/6 inhibition, because that was the treatment setting studied in VIKTORIA-1. The label’s wording and the trial’s entry criteria should both be considered: an indication can be broader than the exact characteristics of the randomized population supporting it.

Other tumor findings remain relevant. ESR1 alterations, changes in the AKT pathway and endocrine sensitivity can affect which approved alternatives are reasonable. The gedatolisib approval adds a biomarker-defined choice; it does not remove the need to place that choice within the patient’s complete treatment history and molecular profile.

Planning treatment with or without palbociclib

The trial supports either gedatolisib plus fulvestrant or the three-drug combination with palbociclib when compared separately with fulvestrant alone. It does not establish a head-to-head advantage for adding palbociclib. Comparing the two hazard ratios or median progression-free survival values directly would bypass randomization because the study’s pivotal comparisons were each against the control group.

Treatment planning may therefore weigh previous response and tolerance to CDK4/6 inhibition, disease tempo, comorbidities, concurrent medications, monitoring demands and patient preferences. The palbociclib-containing regimen introduces the established hematologic and drug-interaction considerations of CDK4/6 inhibition, while both approved options require attention to the adverse reactions and laboratory abnormalities specified in the gedatolisib label.

This distinction is clinically important for a population that has commonly already received a CDK4/6 inhibitor. VIKTORIA-1 shows that a palbociclib-containing gedatolisib regimen can have activity after progression in that treatment context. It should not, however, be read as general evidence that continuing or switching CDK4/6 inhibition after progression is beneficial independently of gedatolisib.

Fulvestrant alone performed poorly in the control group, with median progression-free survival of 2.0 months. The size of the relative effects is notable, but the comparator matters when translating the results to current practice, where several biomarker-directed and non-biomarker-directed options may be available.

Uncertainties after approval

VIKTORIA-1 was randomized and phase 3, strengthening causal inference for each gedatolisib regimen versus fulvestrant. Its open-label design remains a limitation, although independent assessment of progression can reduce some risk of evaluation bias. The study was sponsor-supported, which makes transparent reporting and independent scrutiny of full results important.

The trial was not designed to determine whether the triplet is better than the doublet. Overall survival maturity, patient-reported outcomes, long-term toxicity and outcomes after subsequent therapy will help define the balance between additional disease control and treatment burden.

Generalizability also warrants attention. Trial eligibility can exclude people with poor performance status, substantial organ dysfunction, uncontrolled metabolic disease or other conditions commonly encountered in practice. Biomarker classification may also depend on assay sensitivity and specimen adequacy, particularly when a negative blood-based result is used to infer the absence of a tumor mutation.

Questions clinicians ask

Does every HR-positive, HER2-negative advanced cancer qualify?

No. The indication requires locally advanced or metastatic disease that progressed on or after endocrine therapy and a tumor classified as PIK3CA wild type. The evidence should not be extended to PIK3CA-mutated or untested cancers solely because they share the same hormone receptor and HER2 profile.

Is fresh PIK3CA testing necessary before treatment?

The FDA restriction makes documented mutation status necessary, but the appropriate specimen and assay depend on the labeling and available results. A negative test can be less informative when tumor DNA is insufficient, so clinicians should consider specimen adequacy and whether repeat or tissue-based testing is needed to establish wild-type status reliably.

How should the palbociclib option be chosen?

VIKTORIA-1 supports both regimens against fulvestrant alone but does not provide a randomized comparison between the doublet and triplet. Previous CDK4/6 inhibitor exposure, prior toxicity, marrow reserve, interactions, monitoring burden and patient goals can inform selection without assuming that the numerically longer median for the triplet proves superiority.

Does the approval show that gedatolisib extends survival?

Not yet. The decisive finding was longer progression-free survival, with hazard ratios of 0.24 for the triplet and 0.33 for the doublet versus fulvestrant. Mature overall survival and quality-of-life findings are needed to determine whether delaying progression translates into longer life or a better overall treatment experience.

References

1. FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer — U.S. Food and Drug Administration, 2026
2. Study of Gedatolisib Plus Fulvestrant With and Without Palbociclib in Advanced Breast Cancer (VIKTORIA-1) — ClinicalTrials.gov, 2022
3. Breast Cancer Treatment (PDQ®)–Health Professional Version — National Cancer Institute, 2026